MR Imaging Biomarkers to Monitor Early Response to Hypoxia-Activated Prodrug TH-302 in Pancreatic Cancer Xenografts

TH-302 is a hypoxia-activated prodrug known to activate selectively under the hypoxic conditions commonly found in solid tumors. It is currently being evaluated in clinical trials, including two trials in Pancreatic Ductal Adenocarcinomas (PDAC). The current study was undertaken to evaluate imaging...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:PLoS One
Autori principali: Zhang, Xiaomeng, Wojtkowiak, Jonathan W., Martinez, Gary V., Cornnell, Heather H., Hart, Charles P., Baker, Amanda F., Gillies, Robert
Natura: Artigo
Lingua:Inglês
Pubblicazione: Public Library of Science 2016
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4882075/
https://ncbi.nlm.nih.gov/pubmed/27227903
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0155289
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi